Publications by authors named "J-M Ribera"
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
Histopathology
December 2022
Article Synopsis
- The study focuses on aggressive B-cell non-Hodgkin lymphoma (B-NHL) in HIV patients, specifically exploring its characteristics according to the 2017 WHO classification.
- Researchers analyzed 75 cases using various techniques to evaluate genetic features like MYC, BCL2, and BCL6 status, as well as to assess their influence on prognosis.
- Findings indicate that while certain genetic rearrangements are similar in HIV-positive patients and the general population, a lower frequency of BCL2 rearrangements and specific coexpressions (MYC and BCL2 in DLBCL, MUM1 in Burkitt-like lymphoma) are linked to worse outcomes for those with HIV.
For the last two decades, measurable residual disease (MRD) has become one of the most powerful independent prognostic factors in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, the effect of therapy on the bone marrow (BM) microenvironment and its potential relationship with the MRD status and disease free survival (DFS) still remain to be investigated. Here we analyzed the distribution of mesenchymal stem cells (MSC) and endothelial cells (EC) in the BM of treated BCP-ALL patients, and its relationship with the BM MRD status and patient outcome.
View Article and Find Full Text PDFBCR-ABL1-like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We sought to establish the frequency and outcome of adolescent and adult BCR-ABL1-like ALL using a novel RNA-Seq signature in a series of patients with BCP-ALL. To this end, we developed and tested an RNA-Seq custom panel of 42 genes related to a BCR-ABL1-like signature in a cohort of 100 patients with BCP-ALL and treated with risk-adapted ALL trials.
View Article and Find Full Text PDFBackground: Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory B-cell precursor ALL on the basis of single-group trials that showed efficacy and manageable toxic effects.
Methods: In this multi-institutional phase 3 trial, we randomly assigned adults with heavily pretreated B-cell precursor ALL, in a 2:1 ratio, to receive either blinatumomab or standard-of-care chemotherapy. The primary end point was overall survival.
Article Synopsis
- This study evaluated the outcomes of endovascular treatment for acute ischemic stroke, aiming to identify factors that influence recovery and mortality.
- It analyzed data from a registry involving 536 patients, noting that revascularization significantly improved outcomes while age, stroke severity, and medical history also affected results.
- The findings highlight the importance of timely treatment and revascularization procedures for better recovery rates while outlining additional predictors for patient outcomes after a stroke.